Author/Authors :
JUNNILA, Mika Department of Orthopaedics and Traumatology - Turku University Hospital, Turku , LAAKSONEN, Inari Department of Orthopaedics and Traumatology - Turku University Hospital, Turku , ESKELINEN, Antti Coxa Hospital for Joint Replacement, Tampere , PULKKINEN, Pekka Department of Public Health - Helsinki University, Helsinki, Finland , HAVELIN, Leif Ivar The Norwegian Arthroplasty Register - Department of Orthopaedic Surgery - Haukeland University Hospital, Bergen , FURNES, Ove The Norwegian Arthroplasty Register - Department of Orthopaedic Surgery - Haukeland University Hospital, Bergen , FENSTAD, Anne Marie The Norwegian Arthroplasty Register - Department of Orthopaedic Surgery - Haukeland University Hospital, Bergen , PEDERSEN, Alma B Competence Centre for Clinical Epidemiology and Biostatistics - Department of Clinical Epidemiology - Aarhus University Hospital, Aarhus , OVERGAARD, Søren Department of Orthopaedic Surgery and Traumatology - Odense University Hospital, Odense, and Institute of Clinical Research - University of Southern Denmark, Odense , KÄRRHOLM, Johan The Swedish Hip Arthroplasty Register - Department of Orthopaedics - Institute of Surgical Sciences - Sahlgrenska University Hospital, Gothenburg, Sweden , GARELLICK, Göran The Swedish Hip Arthroplasty Register - Department of Orthopaedics - Institute of Surgical Sciences - Sahlgrenska University Hospital, Gothenburg, Sweden , MALCHAU, Henrik The Swedish Hip Arthroplasty Register - Department of Orthopaedics - Institute of Surgical Sciences - Sahlgrenska University Hospital, Gothenburg, Sweden , MÄKELÄ, Keijo T Department of Orthopaedics and Traumatology - Turku University Hospital, Turku
Abstract :
Background and purpose — According to previous Nordic
Arthroplasty Register Association (NARA) data, the 10-year
implant survival of cemented total hip arthroplasties (THAs) is
94% in patients aged 65–74 and 96% in patients aged 75 or more.
Here we report a brand-level comparison of cemented THA based
on the NARA database, which has not been done previously.
Patients and methods — We determined the rate of implant
survival of the 9 most common cemented THAs in the NARA
database. We used Kaplan-Meier analysis with 95% CI to study
implant survival at 10 and 15 years, and Cox multiple regression
to assess survival and hazard ratios (HRs), with revision for any
reason as endpoint and with adjustment for age, sex, diagnosis,
and femoral head material.
Results — Spectron EF THA (89.9% (CI: 89.3–90.5)) and Elite
THA (89.8% (CI: 89.0–90.6)) had the lowest 10-year survivor-
ship. Lubinus (95.7% survival, CI: 95.5–95.9), MS 30 (96.6%,
CI: 95.8–97.4), and C-stem THA (95.8%, CI: 94.8–96.8) had a
10-year survivorship of at least 95%. Lubinus (revision risk (RR)
= 0.77, CI: 0.73–0.81), Müller (RR = 0.83, CI: 0.70–0.99), MS-30
(RR = 0.73, CI: 0.63–0.86), C-stem (RR = 0.70, CI: 0.55–0.90), and
Exeter Duration THA (RR = 0.84, CI: 0.77–0.90) had a lower risk
of revision than Charnley THA, the reference implant.
Interpretation — The Spectron EF THA and the Elite THA had
a lower implant survival than the Charnley, Exeter, and Lubinus
THAs. Implant survival of the Müller, MS 30, CPT, and C-stem
THAs was above the acceptable limit for 10-year survival.
